From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.
The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed by Cancer Research UK-funded scientists from UCL and The Francis Crick ...
By inferring proliferation rates from single-cell genomics, SPRINTER enhances understanding of tumor evolution and identifies ...
The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been developed by scientists from UCL and The Francis Crick Institute.
The first computer algorithm capable of identifying which tumor cells are driving aggressive cancer growth has been created.
This is among the first times a ctDNA assay has been used in a clinical trial of early-stage lung cancer patients to identify those most likely to benefit from further treatment. As such ...
Broad enrollment criteria appear to have scuttled the trial, which was designed to test whether ctDNA could identify patients ...
Detections of ctDNA at baseline in patients with HR-positive early breast cancer were associated with larger tumor size.
ZEST included patients with stage I-III triple negative breast cancer (TNBC), or BRCA-mutated HER2-BC. Testing for ctDNA-based MRD began any time after the end of definitive treatment, and those ...
A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer ...
is an advanced stage of prostate cancer High ctDNA% identifies aggressive mCRPC A new tool simplifies ctDNA testing, ensuring timely and accurate prostate cancer management Prostate cancer is the ...
Of the 1,901 patients who underwent ctDNA testing to determine their eligibility for the trial, 147 (7.7%) had detectable ctDNA and were therefore eligible. Of these patients, 55% had detectable ...